To address the challenges of prescribing aciclovir in pediatric patients, particularly in the context of rising childhood obesity and the need for improved dosing strategies.
Approach:
Current Prescribing Practices: Developed visualizations of aciclovir dosing using BNFC guidance and UK-WHO growth standard datasets.
Proposed Adjusted Body Weight Model: Investigated the use of adjusted body weight (AdjBW) and a blending function to improve dosing consistency and safety.
Key Findings:
Conventional weight-based and BSA-based dosing may lead to underdosing or toxicity in obese children.
Using AdjBW for BSA calculations improves dosing accuracy at higher weight centiles.
The transition from BSA-based to weight-based dosing at age 12 results in a sharp dose reduction.
Interpretation:
The analysis suggests that using AdjBW in BSA-based dosing offers substantial improvements over current methods, particularly for children above the 50th weight centile.
Limitations:
The model is based on theoretical visualizations and has not been validated against pharmacokinetic or clinical outcome data.
Further evaluation is needed across different sexes and height standard deviation scores.
Conclusion:
The rising prevalence of childhood obesity necessitates a reconsideration of current dosing assumptions.
